← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
📢 Press Releases
Date | Press release |
---|---|
2025-05-27 09:00:00 | Abbott Receives Fda Approval For Tendyne™, First-of-its-kind Device To Replace The Mitral Valve Without Open-heart Surgery The tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (mac) tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair this approval expands abbott’s portfolio of minimally invasive structural heart therapies in the u.s. abbott park, ill., may 27, 2025 /prnewswire/ -- abbott (nyse: abt) today announced the u.s. food and drug administration (fda) has approved the company’s tendyne™ transcatheter mitral valve replacement (tmvr) system to treat people with mitral valve disease. |
2025-05-15 09:05:00 | Abbott’s Libre® Technology Is First Continuous Glucose Monitor Associated With Reduced Hospitalizations For Heart Complications In People With Diabetes New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with type 1 diabetes with prior severe low blood sugar episodes.1 this significant decrease is linked to the use of libre biowearable technology compared to traditional blood glucose monitors.1 results also show a reduction in hospitalization for cardiovascular complications in adults with type 2 diabetes on insulin using libre technology.2 abbott park, ill., may 15, 2025 /prnewswire/ -- abbott (nyse: abt) today announced results from its reflect real-world studies that show the use of freestyle libre® continuous glucose monitoring (cgm) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. |
2025-05-01 09:00:00 | Motoamerica Becomes First Sports Organization To Use Abbott’s Rapid Blood Test For Concussion Evaluation On-site At Races The test, run on abbott’s portable i-stat ® alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes the test will be used by healthcare professionals in the medical facilities at all motoamerica races in 2025 abbott park, ill., and irvine, calif. |
2025-04-29 09:05:00 | Abbott Integrates Libre’s Data With Epic’s Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information Collaboration brings together freestyle libre® systems, the world’s leading continuous glucose monitoring technology (cgm)1 with epic, a healthcare software company, to streamline access to cgm data for healthcare organizations integration empowers u.s. clinicians to enhance patient care by incorporating libre’s data directly into their workflows abbott park, ill., april 29, 2025 /prnewswire/ -- abbott (nyse: abt), the global leader in continuous glucose monitoring (cgm) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 libre cgm systems directly into epic’s electronic health record systems in the u.s. the collaboration aims to improve workflow efficiency for providers through epic’s aura software, which brings health systems together with diagnostics labs and medical device manufacturers. |
2025-04-27 14:15:00 | Abbott Highlights New Aveir™ Data, Initiates Trial For The Company’s Conduction System Pacing Technology Late-breaking data from abbott’s groundbreaking first-in-human study demonstrated successful implantation of the company’s aveir conduction system pacing (csp) leadless pacemaker enrollment has also begun in the ascend csp pivotal clinical trial to evaluate abbott’s investigational csp implantable cardioverter-defibrillator (icd) lead conduction system pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm san diego , april 27, 2025 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data from the aveir™ conduction system pacing (csp) acute clinical feasibility study, which demonstrated the safety and performance of the investigational aveir csp leadless pacemaker technology. the aveir csp acute clinical feasibility study is the world’s first assessment of a leadless pacemaker delivering conduction pacing to the heart’s left bundle branch (lbb) area. |
2025-04-26 19:15:00 |
|
2025-04-16 07:30:00 |
|
2025-03-31 09:00:00 |
|
2025-03-27 09:00:00 |
|
2025-03-26 09:00:00 |
|
2025-03-24 09:00:00 |
|
2025-03-04 11:38:00 |
|
2025-02-21 10:48:00 |
|
2025-02-04 11:27:00 |
|
2025-01-22 07:00:00 |
|

📰 Browse additional press releases for Abbott Laboratories!
Sign up for free or log in📝 Join us and grab your copy of "The Checklist Value Investor — A Smarter Way to Pick Stocks"